Enterprise Value to EBITDA Ratio: TScan (TCRX)
The EV/EBITDA price trend visualization for TScan Therapeutics (TCRX) is 0.00. The share price already prices in the success of primary leukemia trials, while growth is expected from future solid tumor tests. TScan Therapeutics (TCRX) is implementing ESG principles, strictly adhering to biosafety and research ethics. The business relies on its proprietary platform for creating personalized cell therapies for precise tumor targeting.
Analytical breakdowns for tscan.com (TCRX)
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio TScan Therapeutics|TCRX - Long-Term Loans to Capital Ratio|Short-Term Debt to Equity TScan Therapeutics, Inc.|TCRX - Company Total Debt Obligations|Debts to Book Capitalization TCRX|TCRX - Company Long-Term Liabilities|Company Short-Term Debts TScan Therapeutics|Quick Liquidity tscan.com
- business earnings and investment ratios data:
TCRX - Company Profit|Future Profit TScan Therapeutics|TCRX - Company Value to Net Income|Projected Price to Earnings TScan Therapeutics, Inc.|TCRX - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple TCRX|TCRX - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) TScan Therapeutics|TCRX - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months tscan.com|TCRX - Earnings per share increase in current year|Earnings growth forecast for next year TScan Therapeutics
Comprehensive company analysis:TScan TCRX
This ratio correlates the total enterprise value with operating profit before depreciation and amortization, allowing for an assessment of the real value of assets regardless of tax burdens or debt structure. The dynamic EV/EBITDA metric for TScan Therapeutics (TCRX) demonstrates cost management efficiency, which is critical for a biotechnology center minimizing capital expenditures by outsourcing production and clinical trials to third-party contractors.
Competitors of TScan Therapeutics (TCRX)
EV/EBITDA Multiple ONC (BeiGene Corp)|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen Pharma Ltd - Business Value to Operating Income Before Depreciation|BCAX (Bicara Bio) - EV/EBITDA Multiple|Company Value to EBITDA Personalis Genomics PSNL|Enterprise Value to EBITDA Ratio ERAS (Erasca, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio DCTH|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Y-mAbs Therapeutics, Inc. YMAB|Total Company Value to Operating Income Before Depreciation Ratio Aura Biosciences Inc (AURA)|Candel - EV/EBITDA Multiple|Accuray, Inc. (ARAY) - Enterprise Value to EBITDA Ratio|SLS: EV/EBITDA Multiple|actuatetherapeutics.com (ACTU) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Citius Oncology|Enterprise Value to Operating Income Before Depreciation HURA (TuHURA)|Enterprise Value to EBITDA Ratio TARA (Protara)|FATE (Fate Pharma) - Business Value to Operating Income Before Depreciation|Aadi Bioscience - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio CSBR (Champions Oncology Inc)|XBiotech USA - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation CVM (CEL-SCI Corporation)|OSTX: EV/EBITDA Multiple|Company Value to EBITDA Radiopharm Theranostics Ltd (RADX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Artiva Biotherapeutics Inc.|ANL: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple VERU|EV/EBITDA Multiple Tempest Therapeutics Inc (TPST)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Xilio Therapeutics XLO|RENB (Renovaro Biosciences) - Company Value to Operating Income Before Depreciation Ratio|Mural Bio - EV/EBITDA Multiple|Company Value to EBITDA Kairos Pharma Ltd|OKUR (onkuretherapeutics.com) - Enterprise Value to EBITDA Ratio|CytoMed Therapeutics Limited (GDTC) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio CRIS|APLM (Apollomics Corp) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple THAR|Total Company Value to Operating Income Before Depreciation Ratio advanbiomed.com|EV/EBITDA Multiple GNPX (Genprex)|CLDI - Enterprise Value to EBITDA Ratio|SBFM - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Xenetic Biosciences XBIO|SLRX (Salarius Pharmaceuticals) - Enterprise Value to EBITDA Ratio|PPBT: Enterprise Value to Operating Income Before Depreciation Ratio|AONC (American Oncology Network Inc) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio BeiGene Ltd. (BGNE)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Checkpoint Therapeutics, Inc (CKPT)|ELEV (Elevation Oncology Inc.) - Business Value to Operating Income Before Depreciation|iCAD - Enterprise Value to EBITDA Ratio|IKNA: Enterprise Value to Operating Income Before Depreciation|Notable Labs - EV/EBITDA Multiple|Viracta Therapeutics (VIRX) - Enterprise Value to EBITDA Ratio|MOR: EV/EBITDA Multiple|NAYA Biosciences Corp (NAYA) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Ascentage Pharma Group
